Changes in Beneficial Ownership · 4
BioAge Labs, Inc.
BIOANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06122026_080608.xml
Filing details
- Report period
- 2026-06-10
- Issuer
- BioAge Labs, Inc.
- Issuer CIK
- 0001709941
- Trading symbol
- BIOA
Reporting owner 1
- Name
- Pande Vijay Satyanand
- Reporting owner CIK
- 0001840663
- Relationship
- Director
- Address
- C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE, CA, 94608
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 15.48 | 2026-06-10 | A · Form 4 | 22,000 | A | 0 | [F1] | 2036-06-09 | Common Stock | 22,000 | 22,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ Dov A. Goldstein as attorney-in-fact
- Date
- 2026-06-12
Company context
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including diabetic macular edema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular proof-of-concept data from QUELL-CV are anticipated in the fourth quarter of 2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated in the second half of 2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAgeʼs additional preclinical programs, which leverage insights from the Companyʼs proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.